Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Neurol ; 247(9): 687-90, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11081807

RESUMO

Lipoprotein(a) [Lp(a)] has been identified as an independent risk factor for vascular diseases. There are no data on Lp(a) levels in patients on long-term medication with carbamazepine, phenytoin, phenobarbital, or valproate. To investigate the effects of such treatment on Lp(a) levels and common carotid artery intima media thickness we studied 51 epileptic outpatients on long-term antiepileptic medication and 51 age-and sex-matched controls. Lp(a) levels above 45 mg/dl were found in 11 of 50 patients, but in only 4 of 51 controls (P < 0.05). The mean serum concentration of Lp(a) was 33.0+/-7.0 mg/dl in patients and 16.9+/-2.7 mg/dl in controls (P < 0.05). Epileptic patients also had a thicker intima media of the common carotid artery (0.79+/-0.04 mm) than controls (0.69+/-0.02 mm, P < 0.05) as measured by B-mode ultrasonography. Our results suggest an untoward effect of long-term antiepileptic medication on Lp(a) serum concentrations. Elevated Lp(a) levels might be a risk factor for arteriosclerosis in epileptic patients.


Assuntos
Anticonvulsivantes/efeitos adversos , Epilepsia/tratamento farmacológico , Lipoproteína(a)/sangue , Adulto , Anticonvulsivantes/administração & dosagem , Arteriosclerose/induzido quimicamente , Estenose das Carótidas/induzido quimicamente , Feminino , Humanos , Lipoproteína(a)/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Fatores de Tempo
2.
Epilepsia ; 40(3): 345-50, 1999 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10080517

RESUMO

PURPOSE: Homocysteine is an experimental convulsant and an established risk factor in atherosclerosis. A nutritional deficiency of vitamin B6, vitamin B12, or folate leads to increased homocysteine plasma concentrations. During treatment with carbamazepine (CBZ), phenytoin, or phenobarbital, a deficiency in these vitamins is common. The objective of the study was to test the hypothesis that antiepileptic drug (AED) treatment is associated with increased homocysteine plasma concentrations. METHODS: A total of 51 consecutive outpatients of our epilepsy clinic receiving stable, individually adjusted AED treatment and 51 sex- and age-matched controls were enrolled in the study. Concentrations of total homocysteine and vitamin B6 were measured in plasma; vitamin B12 and folate were measured in the serum of fasted subjects. RESULTS: Patients and controls differed significantly in concentrations of folate ( 13.5+/-1.0 vs. 17.4+/-0.8 nM and vitamin B6 (39.7+/-3.4 vs. 66.2+/-7.5 nM), whereas serum concentrations of vitamin B12 were similar. The homocysteine plasma concentration was significantly increased to 14.7+/-3.0 microM in patients compared with controls (9.5+/-0.5 microM; p < 0.05, Wilcoxon rank-sum test). The number of patients with concentrations of >15 microM was significantly higher in the patient group than among controls. The same result was obtained if only patients with CBZ monotherapy were included. Patients with increased homocysteine plasma concentrations had lower folate concentrations. CONCLUSIONS: These data support the hypothesis that prolonged AED treatment may increase plasma concentrations of homocysteine, although the alternative explanation that increased homocysteine plasma concentrations are associated with the disease and not the treatment cannot be completely excluded at the moment.


Assuntos
Anticonvulsivantes/efeitos adversos , Anticonvulsivantes/uso terapêutico , Epilepsia/sangue , Epilepsia/tratamento farmacológico , Homocisteína/sangue , Fatores Etários , Assistência Ambulatorial , Anticonvulsivantes/farmacologia , Carbamazepina/efeitos adversos , Carbamazepina/farmacologia , Carbamazepina/uso terapêutico , Convulsivantes/sangue , Depressão Química , Jejum/sangue , Feminino , Ácido Fólico/sangue , Deficiência de Ácido Fólico/induzido quimicamente , Humanos , Masculino , Pessoa de Meia-Idade , Fenobarbital/efeitos adversos , Fenobarbital/farmacologia , Fenobarbital/uso terapêutico , Fenitoína/efeitos adversos , Fenitoína/farmacologia , Fenitoína/uso terapêutico , Piridoxina/sangue , Fatores de Risco , Fatores Sexuais , Ácido Valproico/efeitos adversos , Ácido Valproico/farmacologia , Ácido Valproico/uso terapêutico , Vitamina B 12/sangue , Deficiência de Vitamina B 12/induzido quimicamente , Deficiência de Vitamina B 6/induzido quimicamente
3.
J Pediatr Health Care ; 6(5 Pt 2): 325-32, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1453288

RESUMO

Children with short stature may experience academic difficulties, psychologic impairment, and emotional stress related to an underlying medical condition or social stigmatization. Educational and psychosocial problems associated with short stature often can be alleviated with appropriate interventions. Parents, health-care practitioners, and teachers should be aware of the potential academic, psychologic, and social problems related to short stature and growth delay, so they can support the short child's normal development and intervene promptly if problems arise.


Assuntos
Estatura , Transtornos do Crescimento/psicologia , Criança , Aconselhamento , Transtornos do Crescimento/complicações , Transtornos do Crescimento/enfermagem , Humanos , Inteligência , Relações Interpessoais , Enfermagem Pediátrica , Autoimagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA